Identifying drugs needing pharmacogenetic monitoring in a Korean hospital.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  American Journal of Health-System Pharmacy

• Publication date

  2007-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.2146/AJHP050490PMID 17215467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements

  2006cited by this paper
• A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.

  2005cited by this paper
• Clinical Consequences of Cytochrome P450 2C9 Polymorphisms

  2005cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

  2005cited by this paper
• Drug metabolism and variability among patients in drug response.

  2005cited by this paper
• CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia

  2005cited by this paper
• Allele and genotype frequencies of CYP2C9 in a Korean population.

  2005cited by this paper
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

  2004cited by this paper
• MICROMEDEX® Healthcare Series

  2004cited by this paper
• Moving towards individualized medicine with pharmacogenomics

  2004cited by this paper
• Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states

  2004cited by this paper
• Therapeutic Monitoring of Antidepressants in the Era of Pharmacogenetics Studies

  2004cited by this paper
• Codeine intoxication associated with ultrarapid CYP2D6 metabolism.

  2004cited by this paper
• Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

  2003cited by this paper
• Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.

  2003cited by this paper
• Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

  2002cited by this paper
• Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

  2002cited by this paper
• The genetic basis of variability in drug responses

  2002cited by this paper
• Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• Genetic basis of drug metabolism.

  2002cited by this paper
• Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

  2002cited by this paper
• Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.

  2002cited by this paper
• Pharmacogenetic screening and therapeutic drugs.

  2002cited by this paper
• Continuing-education programs in pharmacogenomics for pharmacists.

  2002cited by this paper
• Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics

  2002cited by this paper
• Pharmacogenetics

  2001cited by this paper
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001cited by this paper
• Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.

  2001cited by this paper
• Molecular basis of ethnic differences in drug disposition and response.

  2001cited by this paper
• Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy.

  2001cited by this paper
• Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.

  2001cited by this paper
• Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects

  2000cited by this paper
• Pharmacogenetics and adverse drug reactions.

  2000cited by this paper
• Assessing the cost-effectiveness of pharmacogenomics

  2000cited by this paper
• Pharmacogenomics: The promise of personalized medicine

  2000cited by this paper
• Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

  2000cited by this paper
• Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

  2000cited by this paper
• Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

  1999cited by this paper
• Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro.

  1999cited by this paper
• Pharmacogenomics: worthy of pharmacy's attention.

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.

  1999cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects

  1999cited by this paper
• 10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

  1998cited by this paper
• Drug Information Handbook

  1998cited by this paper
• Pharmacokinetics of nortriptyline and its 10‐hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes

  1998cited by this paper
• Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine.

  1997cited by this paper
• Nomenclature for human CYP2D6 alleles.

  1996cited by this paper
• Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.

  1996cited by this paper
• The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry

  1996cited by this paper
• Metabolism of aceclofenac in humans.

  1996cited by this paper
• CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.

  1996cited by this paper
• The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.

  1996cited by this paper
• AHFS Drug Information

  1994cited by this paper
• Pharmacokinetic Optimisation of the Treatment of Psychosis

  1993cited by this paper

• Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects

  2021cites this paper
• The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy

  2020cites this paper
• VHRM_A_230639 241..248

  2020cites this paper
• Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events.

  2020cites this paper
• Genetic Testing for Opioid Pain Management: A Primer

  2017cites this paper
• A bioequivalence study of two omeprazole formulations in healthy male volunteers.

  2016cites this paper
• Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.

  2016cites this paper
• Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus

  2015cites this paper
• Opioid pharmacogenetics in anesthesia and pain management

  2015cites this paper
• Evaluation of a Fully Automated, Rapid Detection System for CYP2C19 and UGT1A1 Genotyping

  2014cites this paper
• Estudio piloto desde la farmacia comunitaria sobre el efecto farmacogenético del CYP 2C9, 2D6 y 3A4 y el seguimiento farmacoterapéutico en la terapia antihipertensiva

  2014cites this paper
• Pharmacokinetic and bioequivalence evaluation of two formulations of levocetirizine 5 mg in healthy Thai volunteers

  2013cites this paper
• CYP450 Enzymes in Drug Discovery and Development: An Overview

  2012cites this paper
• Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs.

  2011cites this paper
• Bioequivalence and pharmacokinetic evaluation of two formulations of glimepiride 2 mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers.

  2010cites this paper
• Pharmacokinetics and bioequivalence of 20 mg omeprazole capsule in 24 healthy Korean male volunteers.

  2009cites this paper
• Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.

  2009cites this paper
• Relative bioavailability of generic and branded 250-mg and 500-mg oral chlorphenesin carbamate tablets in healthy Korean volunteers: a single-dose, randomized-sequence, open-label, two-period crossover trial.

  2009cites this paper
• Bioequivalence and pharmacokinetic evaluation of two branded formulations of aceclofenac 100 mg: a single-dose, randomized, open-label, two-period crossover comparison in healthy Korean adult volunteers.

  2008cites this paper
• Prioritising the prevention of medication handling errors

  2008cites this paper
• Cytochrome P450s in the development of target-based anticancer drugs.

  2008cites this paper
• Influence of genetic variability on the clinical pharmacology of carbamazepine and lamotrigine

  2007cites this paper
• Ideals and idealists: striving to achieve our societal imperative.

  2007cites this paper